The global landscape of non-Hodgkin lymphoma incidence and mortality in 2022 and projections to 2045.

IF 3.6 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Archives of Medical Science Pub Date : 2026-05-11 eCollection Date: 2026-01-01 DOI:10.5114/aoms/218811
Zhixing Kuang, Lingling Zheng, Lilin Yan, Rongqiang Liu, Xinfei Zheng, Aihua Ye, Jiannan Tu
{"title":"The global landscape of non-Hodgkin lymphoma incidence and mortality in 2022 and projections to 2045.","authors":"Zhixing Kuang, Lingling Zheng, Lilin Yan, Rongqiang Liu, Xinfei Zheng, Aihua Ye, Jiannan Tu","doi":"10.5114/aoms/218811","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Updated estimates of the current and future burden of non-Hodgkin lymphoma (NHL) are critical for evaluating global cancer control efforts and addressing disparities in disease impact across regions.</p><p><strong>Material and methods: </strong>We assessed the 2022 global NHL burden and projected trends to 2045 across 185 countries using population-based cancer registry data from the Cancer Incidence in Five Continents (CI5) database and GLOBOCAN 2022 estimates. Trends in age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) from 1990 to 2017/2020 were analyzed in selected regions to contextualize findings.</p><p><strong>Results: </strong>In 2022, an estimated 553,389 new NHL cases (ASIR 5.6/100,000) and 250,679 deaths (ASMR 2.4/100,000) occurred globally. The highest case numbers were observed at ages 65-69, with ASIR peaking at 85+ and men consistently showing higher rates. High-HDI regions, such as Northern America (ASIR 12.49) and Australia/New Zealand (ASIR 12.05), reported elevated incidence compared to low-HDI regions like South-Central Asia (ASIR 2.79). East Asia, led by China (14.6% of cases), had the largest case volume. ASIR strongly correlated with HDI (<i>r</i> = 0.655, <i>p</i> = 3.21E-22), while ASMR showed no significant correlation (<i>r</i> = 0.002, <i>p</i> = 0.982). By 2045, NHL cases are projected to increase to 889,841 and deaths to 433,254, with low-HDI regions experiencing the steepest rises.</p><p><strong>Conclusions: </strong>Our findings reveal pronounced global disparities in NHL burden, with high-HDI regions benefiting from treatment advances, while low-HDI areas face escalating challenges by 2045. Addressing aging-driven incidence, expanding diagnostic capacity in resource-limited settings, and strengthening prevention efforts are imperative to tackle these inequities and curb the projected burden.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"22 3","pages":"1312-1325"},"PeriodicalIF":3.6000,"publicationDate":"2026-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13426179/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/aoms/218811","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Updated estimates of the current and future burden of non-Hodgkin lymphoma (NHL) are critical for evaluating global cancer control efforts and addressing disparities in disease impact across regions.

Material and methods: We assessed the 2022 global NHL burden and projected trends to 2045 across 185 countries using population-based cancer registry data from the Cancer Incidence in Five Continents (CI5) database and GLOBOCAN 2022 estimates. Trends in age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) from 1990 to 2017/2020 were analyzed in selected regions to contextualize findings.

Results: In 2022, an estimated 553,389 new NHL cases (ASIR 5.6/100,000) and 250,679 deaths (ASMR 2.4/100,000) occurred globally. The highest case numbers were observed at ages 65-69, with ASIR peaking at 85+ and men consistently showing higher rates. High-HDI regions, such as Northern America (ASIR 12.49) and Australia/New Zealand (ASIR 12.05), reported elevated incidence compared to low-HDI regions like South-Central Asia (ASIR 2.79). East Asia, led by China (14.6% of cases), had the largest case volume. ASIR strongly correlated with HDI (r = 0.655, p = 3.21E-22), while ASMR showed no significant correlation (r = 0.002, p = 0.982). By 2045, NHL cases are projected to increase to 889,841 and deaths to 433,254, with low-HDI regions experiencing the steepest rises.

Conclusions: Our findings reveal pronounced global disparities in NHL burden, with high-HDI regions benefiting from treatment advances, while low-HDI areas face escalating challenges by 2045. Addressing aging-driven incidence, expanding diagnostic capacity in resource-limited settings, and strengthening prevention efforts are imperative to tackle these inequities and curb the projected burden.

2022年全球非霍奇金淋巴瘤发病率和死亡率及2045年预测
对当前和未来非霍奇金淋巴瘤(NHL)负担的最新估计对于评估全球癌症控制工作和解决不同地区疾病影响差异至关重要。材料和方法:我们使用来自五大洲癌症发病率(CI5)数据库和GLOBOCAN 2022估计的基于人群的癌症登记数据,评估了2022年全球NHL负担,并预测了185个国家到2045年的趋势。分析了1990年至2017/2020年部分地区年龄标准化发病率(ASIR)和年龄标准化死亡率(ASMR)的趋势,以将研究结果背景化。结果:2022年,全球估计发生553,389例NHL新病例(ASIR 5.6/100,000)和250,679例死亡(ASMR 2.4/100,000)。最高的病例数出现在65-69岁,ASIR在85岁以上达到高峰,男性的发病率一直较高。据报道,与中南亚等低hdi地区(ASIR 2.79)相比,北美(ASIR 12.49)和澳大利亚/新西兰(ASIR 12.05)等高hdi地区的发病率较高。以中国为首的东亚地区(占病例数的14.6%)病例数最多。ASIR与HDI呈显著相关(r = 0.655, p = 3.21E-22), ASMR与HDI无显著相关(r = 0.002, p = 0.982)。到2045年,NHL病例预计将增加到889,841例,死亡人数将增加到433,254人,其中低人类发展指数地区的上升幅度最大。结论:我们的研究结果揭示了全球NHL负担的显著差异,高hdi地区受益于治疗进展,而低hdi地区到2045年将面临不断升级的挑战。应对老龄化驱动的发病率,在资源有限的情况下扩大诊断能力,并加强预防工作,对于解决这些不公平现象和控制预计负担至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Archives of Medical Science
Archives of Medical Science 医学-医学:内科
CiteScore
4.90
自引率
7.90%
发文量
139
审稿时长
1.7 months
期刊介绍: Archives of Medical Science (AMS) publishes high quality original articles and reviews of recognized scientists that deal with all scientific medicine. AMS opens the possibilities for young, capable scientists. The journal would like to give them a chance to have a publication following matter-of-fact, professional review by outstanding, famous medical scientists. Thanks to that they will have an opportunity to present their study results and/or receive useful advice about the mistakes they have made so far. The second equally important aim is a presentation of review manuscripts of recognized scientists about the educational capacity, in order that young scientists, often at the beginning of their scientific carrier, could constantly deepen their medical knowledge and be up-to-date with current guidelines and trends in world-wide medicine. The fact that our educational articles are written by world-famous scientists determines their innovation and the highest quality.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书